Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis

Documenti analoghi

• Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
  di: Muhammad Aaqib Shamim, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
  di: Frederick Berro Rivera, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
  di: Lucas A. Mavromatis, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
  di: Robert L. Dubin, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
  di: Giovanni Antonio Silverii, et al.
  Pubblicazione: (2024)